Loading asset research
Aurinia Pharmaceuticals Inc Ordinary Shares
AUPHNasdaq · USD · StocksQuote as of · Exchange session not verified$16.09
-0.09%
Today
AUPH
Loading 1D prices…
Market cap
$2.1B
Volume
745.4K
52w high
$19.2552w low
$10.34Company profile
Aurinia Pharmaceuticals Inc Ordinary Shares
Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential treatment of autoimmune diseases. The company was founded in 1993 and is headquartered in Edmonton, Canada.
Sector
Health Care
Industry
Pharmaceutical Preparations
Exchange
Nasdaq
Display currency
USD
Location
Edmonton, AB, United States
Employees
128
Fiscal year end
1231
CIK
1600620
Session & valuation
Open$16.28
Previous close$16.11
Day high$16.35
Day low$16.06
30-day avg. volume1.1M
Outstanding shares133.1M
Diluted EPS$2.07
Latest annual period
P/E (trailing)7.06
P/E (forward)15.09
Price / book3.48
Beta1.41
Dividend yield—
Deterministic peer set
Companies with SEC SIC 2834
Exact regulatory industry matches, ranked by nearest market capitalization.
| Company | Market cap | Revenue | Net margin | Diluted EPS | Today | Consensus |
|---|---|---|---|---|---|---|
| NUVBNuvation Bio Inc. Class A Common Stock | $2.1B | $62.9M | -325.31% | -$0.60 | -3.42% | Buy |
| SRPTSarepta Therapeutics Inc. Common Stock (DE) | $2.2B | $1.9B | -38.27% | -$7.13 | -0.29% | Hold |
| PVLAPalvella Therapeutics Inc. Common Stock | $2.2B | $0.00 | — | -$3.71 | -0.17% | Buy |
| BHCBausch Health Companies Inc. Common Stock | $2.2B | $10.3B | +1.53% | $0.42 | -3.46% | Hold |
| RAPPRapport Therapeutics Inc. Common Stock | $2.1B | $0.00 | — | -$2.86 | +0.69% | Buy |